High concentration medicant solutions for treating neurological disorders

Abstract

Highly concentrated solutions are disclosed along with methods of inhibiting and/or ameliorating functional neurological disorders of the brain. The method may include administering directly to a brain of a subject a medicament multiple times over a time period of at least two days. The medicament may include a half-life of less than 2 hour in the cerebrospinal fluid. The method may include inhibiting and/or ameliorating a functional neurological disorder of the brain using the medicant.

1 - 19 . (canceled) 
     
     
         20 . A method of treating epilepsy a subject, comprising:
 administering a pharmaceutical composition comprising from 200 mg/ml to 500 mg/ml valproic acid or a pharmaceutically acceptable salt thereof directly to cerebrospinal fluid of the subject-over a time period of at least two days; thereby treating the epilepsy in the subject.   
     
     
         21 . The method of  claim 20 , wherein during treatment the valproic acid or the pharmaceutically acceptable salt thereof has a concentration in the cerebrospinal fluid of between about 1 microgram/ml to 500 micrograms/ml. 
     
     
         22 . The method of  claim 21 , further comprising determining the concentration of the valproic acid or the pharmaceutically acceptable salt thereof in the cerebrospinal fluid by sampling the cerebrospinal fluid and performing a test of the concentration in the sampled cerebrospinal fluid. 
     
     
         23 . The method of  claim 22 , further comprising changing a flow rate of administration of the pharmaceutical composition to the cerebrospinal fluid to maintain the concentration in the cerebrospinal fluid of between about 1 microgram/ml to 500 micrograms/ml. 
     
     
         24 . The method of  claim 20 , wherein administering the pharmaceutical composition to the cerebrospinal fluid comprises administering the pharmaceutical composition to a cerebral ventricle. 
     
     
         25 . The method of  claim 20 , wherein the pharmaceutical composition is only administered to one lateral ventricle on one side of the brain and not bilaterally administered to both ventricles. 
     
     
         26 . The method of  claim 20 , wherein administering the pharmaceutical composition to the cerebrospinal fluid comprises substantially continuous administration of the pharmaceutical composition during treatment via a catheter. 
     
     
         27 . The method of  claim 20 , wherein administering the pharmaceutical composition to the cerebrospinal fluid comprises administration via multiple bolus pulses of the pharmaceutical composition during treatment. 
     
     
         28 . The method of  claim 20 , wherein the pharmaceutical composition comprises citric acid, an acetate, and a phosphate. 
     
     
         29 . The method of  claim 20 , wherein the pharmaceutical composition comprises citric acid. 
     
     
         30 . The method of  claim 20 , further comprising changing a daily flow rate of the pharmaceutical composition to the cerebrospinal fluid to enhance treatment of the epilepsy.